Clinical Trial Update: Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation [Phase 1]

View source ↗

Summary

Phase 1 relative bioavailability study in healthy subjects evaluating the pharmacokinetics of HTL0009936 after a single dose of the prototype formulation; statu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• HTL0009936

Snippet

Sponsor: Nxera Pharma UK Limited | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED